about
Secondary psychosis induced by metabolic disordersAutism as a disorder of biological and behavioral rhythms: toward new therapeutic perspectivesThe hidden Niemann-Pick type C patient: clinical niches for a rare inherited metabolic disease.Rationale and protocol for using a smartphone application to study autism spectrum disorders: SMARTAUTISM.Pain reactivity and plasma beta-endorphin in children and adolescents with autistic disorderDiagnostic and treatment implications of psychosis secondary to treatable metabolic disorders in adults: a systematic review.Modulation of brain β-endorphin concentration by the specific part of the Y chromosome in mice.Gene × Environment interactions in autism spectrum disorders: role of epigenetic mechanisms.Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challengesAnimal models relevant to schizophrenia and autism: validity and limitations.[Treatable neurometabolic diseases. Association with schizophrenia spectrum disorders].PHEDRE trial protocol - observational study of the prevalence of problematic use of Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO) and analgesics in the French sickle-cell disease population.Influence of socioeconomic status on antipsychotic prescriptions among youth in FranceIncidence of adverse events in antipsychotic-naïve children and adolescents treated with antipsychotic drugs: a French multicentre naturalistic study protocol (ETAPE)Are patients with schizophrenia insensitive to pain? A reconsideration of the question.Electroconvulsive therapy in adolescents with the catatonia syndrome: efficacy and ethics.Are impairments of time perception in schizophrenia a neglected phenomenon?Children's synchrony and rhythmicity in imitation of peers: toward a developmental model of empathy.The neuropsychiatry of inborn errors of metabolism.Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature.[Clinic of somatoform disorders in abused adolescents].Lorazepam, fluoxetine and packing therapy in an adolescent with pervasive developmental disorder and catatonia.Cerebrotendinous xanthomatosis presenting with severe externalized disorder: improvement after one year of treatment with chenodeoxycholic Acid.Maternal exposure to lorazepam and anal atresia in newborns: results from a hypothesis-generating study of benzodiazepines and malformations.[In utero exposure to benzodiazepine. Is there a risk for anal atresia with lorazepam?][Drug treatment of early-onset schizophrenia].Psychiatric and neurological symptoms in patients with Niemann-Pick disease type C (NP-C): Findings from the International NPC Registry.Altered circadian patterns of salivary cortisol in low-functioning children and adolescents with autism.Autism spectrum disorder: an early and frequent feature in cerebrotendinous xanthomatosis.Medical and developmental risk factors of catatonia in children and adolescents: a prospective case-control study.Oculomotor Impairments in Developmental Dyspraxia.Systematic review of psychiatric signs in Niemann Pick disease type C.[Schizophrenic disorders in adolescence].Does catatonia influence the phenomenology of childhood onset schizophrenia beyond motor symptoms?[Schizophrenia and pain reactivity].[Time perception and schizophrenia: Phenomenological and neuropsychological approach].Time perception of simultaneous and sequential events in early-onset schizophrenia.Children and adolescents with severe mental illness need vitamin D supplementation regardless of disease or treatment.[Psychiatric and cognitive signs associated with inborn errors of metabolism].
P50
Q27015730-A9537F17-FCED-4DD6-AFE9-E2E2D5B0986BQ28080719-E95A1B4F-F849-4DB0-9391-8406021F1E8DQ30235362-180A0169-71EC-42D8-B32E-EABFE7CAD091Q33451588-FF9D4231-7813-443A-8520-7802CFD25171Q33496741-6E938B21-8980-4C88-8B48-378B3BF6AA4AQ33707443-C45D3680-DDD5-46EE-B63E-82AC027667AAQ33847739-9BC890EA-A5CE-46D9-8CC2-54625D85C48FQ33997473-0F6C585A-968B-46EB-A372-DADDA110DA84Q34271687-4C11B661-7AFC-430C-AACF-F6E650E44F27Q34580449-3D924B05-6DD2-4FC2-BB64-ADFFD3DE692BQ34589765-C0D7AF8E-E9C7-4A74-9DF8-B1E870E9CB86Q34672087-9859EB31-C9BA-4EDB-A36B-42AAD752B4DDQ35843141-62563163-9393-4003-AA7E-87A2F3103903Q36292249-D10360CF-9D70-4A41-B17C-09D267B2E916Q36773233-F22D812A-86A3-49E3-8DF6-F9654706E994Q37427363-36EFA2AB-B59A-4529-9C18-4267F53B065BQ37811741-0523FCDF-380A-4F9F-889C-B08E02F230BBQ37908679-F667575F-0A62-4C6B-B9DA-E5A9F537F5BDQ38098776-4E0B0BCD-C04C-4E19-927F-786E882F89D6Q38108763-4E1EB9C6-7ED1-4A91-BF5D-CBBC4907E448Q38638685-EE3E4515-C1CD-462F-AC75-058F2B9CBE48Q40832310-5FDB5DFF-31D2-41FC-856B-2EC6C1BF1AF3Q42871425-F29DE824-AD93-48FB-A0D1-A82D778C9EC4Q43088043-342B5C7B-F7FD-44A9-B99D-19F178CACA01Q43689748-5ACE2E21-415B-42B0-AAEA-E0F3DF63990FQ44804266-F29B6E29-A057-442C-9BD5-DCCEFB1A86FBQ46690464-4F2D7F83-1770-4EEC-ACD3-3FD8A6EC5A7AQ47980087-24814B71-F7EF-4F7D-8AD2-88A030B0A67DQ48028650-881003FC-F350-4E52-812E-8C121E9E3C85Q48089273-AEE3228D-BA53-4AED-BCD9-B67DF560F288Q48254999-59EFFFD5-0012-4760-88E0-8483C1AA1F72Q48592522-6EDF82A9-FE1C-462D-AE18-C7943E29E84FQ49849629-A108427F-4540-4AE9-9B6F-1D3C35C711BAQ50306825-FB360AA0-073E-4C2C-A919-EF8ADDA29F00Q50310636-A254CF11-086D-4BFD-B74D-ED68ED664BF9Q50345996-711B51D3-8149-43BA-BCB9-4F138CFFB3F6Q50541168-63D83889-B55D-4EDC-9D93-22AA842A36B1Q50637552-08D90C6B-B780-41C1-9E67-4A5ED3671108Q51804247-F279E23E-9C08-4345-9FD1-F18677AE446BQ51848918-4CBB4143-4608-4325-B6C6-5117083C626A
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Olivier Bonnot
@ast
Olivier Bonnot
@en
Olivier Bonnot
@es
Olivier Bonnot
@nl
Olivier Bonnot
@sl
type
label
Olivier Bonnot
@ast
Olivier Bonnot
@en
Olivier Bonnot
@es
Olivier Bonnot
@nl
Olivier Bonnot
@sl
prefLabel
Olivier Bonnot
@ast
Olivier Bonnot
@en
Olivier Bonnot
@es
Olivier Bonnot
@nl
Olivier Bonnot
@sl
P106
P21
P31
P496
0000-0003-0005-4765